BioSpace News Archive

BrainsWay Ltd. today reported second quarter 2022 financial results and provided an operational update.

HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has received a milestone payment under its October 2020 research collaboration and service agreement with Takeda.

BridgeBio Pharma, Inc. and Sentynl Therapeutics, Inc., along with partner Medison Pharma announced that the State of Israel Ministry of Health has approved NULIBRY® for Injection as the first therapy in Israel to treat MoCD Type A with the indication to reduce the risk of mortality for patients with molybdenum cofactor deficiency Type A.

Gemini Therapeutics, Inc. and Disc Medicine, Inc. announced today that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.

Caladrius Biosciences, Inc. and Cend Therapeutics, Inc. (“Cend”), today announced Cend’s execution of a collaboration agreement with F. Hoffmann-La Roche Ltd.(“Roche”) to evaluate Cend’s lead investigational drug, CEND-1.

Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-improving medical products, today announces the completion and safety findings from Cohort I of its Multi-Day Ascending Dosing (MAD) arm for its Phase I Clinical Trial.

Outlook Therapeutics, Inc. today announced its financial results for its fiscal third quarter ended June 30, 2022.

UC Davis, a leading university in molecular imaging that collaborated with United Imaging to develop the world’s first total-body PET/CT scanner, ‘uEXPLORER®,’ recently presented their research on COVID-19 at the 2022 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting.

DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, today announced it would release its financial results for the second quarter ended June 30, 2022, on Monday, August 15, 2022.

VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, has announced a sponsored research agreement with The University of Texas MD Anderson Cancer Center to evaluate the role of neutrophil extracellular traps (“NETs”) in cancer patients with sepsis.